WHAT IS COXSACKIE A OR B VIRUS TITER TEST?

WHAT IS COXSACKIE A OR B VIRUS TITER TEST?

The coxsackievirus is divided into two antigenically different groups, A and B, and is of the enterovirus family. Enteroviruses are easily transmitted by the faecal-oral route and are associated with epidemics, especially in newborn nurseries. Although blood is rarely used for isolation of viruses, serologic testing may be performed to detect Coxsackie A virus or Coxsackie B virus antibodies. Twenty-three species of Coxsackie A exist. Types 1, 4, 9, 16, and 23 may infect the heart, causing pericarditis progressing to heart failure. Hand, foot and mouth disease (HFMD) is a viral infection caused by Coxsackie A virus, usually occurring in ages 10 years and younger. Coxsackie type A is also associated with a severe form of conjunctivitis and with respiratory disease. Six species of Coxsackie B exist. Types 1 to 5 may infect the heart, causing pericarditis progressing to heart failure. These same types may cause pleurodynia, a disease of limited duration (1 week) in which the client experiences the acute onset of the chest or abdominal pain along with fever and headache. Types 2 to 5 cause most cases of viral meningitis. This test involves measuring the antibody levels in both an acute and a convalescent sample of blood to detect an increase in the titer. It is a neutralisation test in which diluted samples (1 : 2, 1 : 8, 1 : 32, 1 : 128, 1 : 512) are mixed with Coxsackie A virus or Coxsackie B virus, inoculated onto a cell culture system, and observed for antigen-antibody reactions for up to 7 days. Enterovirus antibodies respond very quickly to infection; thus, the earlier the acute sample is collected, the better the chance of detecting a positive test. 

 

KNOWLEDGE BASE
About Genomic Medicine UK

Genomic Medicine UK is the home of comprehensive genomic testing in London. Our consultant medical doctors work tirelessly to provide the highest standards of medical laboratory testing for personalised medical treatments, genomic risk assessments for common diseases and genomic risk assessment for cancers at an affordable cost for everybody. We use state-of-the-art modern technologies of next-generation sequencing and DNA chip microarray to provide all of our patients and partner doctors with a reliable, evidence-based, thorough and valuable medical service.

X